Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Fresenius faces more than 5,500 NaturaLyte, GranuFlo lawsuits

Posted: July 30, 2014

Fresenius Medical Care, the world’s largest provider of dialysis services and products, is facing more than 5,500 lawsuits alleging the company’s dialysis concentrates caused patients to suffer sudden cardiac arrest.

New meta-analysis raises serious questions about SSRI use during pregnancy

Posted: July 30, 2014

There is not enough research to provide a clear guidance on the risks or benefits of antidepressant use during pregnancy, however there are serious concerns regarding the drugs’ affects on newborns that should be addressed, a new meta-analysis has found.

European advisors recommend approval of new combination type 2 diabetes treatment

Posted: July 29, 2014

An advisory panel for European drug regulators is recommending approval for a new type 2 diabetes drug combining the long-acting insulin degludec with Victoza (liraglutide). The favorable recommendation of Novo Nordisk’s drug Xultophy, previously known as IDegLira, was based on

Risperidone side effects send patients to the emergency room

Posted: July 28, 2014

Adverse effects of antipsychotic medications such as Risperdal (risperidone) send more than 20,000 people in the United States to the emergency room each year, prompting the American Psychiatric Association to issue an advisory to clinicians to carefully evaluate patients before

Acetaminophen as effective as placebo in treating lower back pain

Posted: July 28, 2014

The commonly used painkiller acetaminophen, the same drug in over-the-counter Tylenol, doesn’t relieve lower-back pain any better than a placebo, according to a new study published in the journal The Lancet.

FDA approves oxycodone combination drug that resists abuse

Posted: July 27, 2014

A powerful combination opioid painkiller whose euphoric effects can be rendered inactive if the drug is tampered with has been approved by the Food and Drug Administration (FDA). The drug’s formulation aligns with the agency’s commitment to combat the misuse

FDA grants breakthrough designation to new pancreatic cancer treatment

Posted: July 27, 2014

A new pancreatic cancer combination treatment has been granted Breakthrough Therapy Designation by the Food and Drug Administration (FDA), giving new options for patients with metastatic pancreatic cancer.

Teen’s death prompts FDA warning for consumers to avoid pure caffeine powder

Posted: July 26, 2014

Logan Stiner was just days away from his high school graduation when he died after consuming a lethal dose of powdered caffeine. The teen’s death prompted a Food and Drug Administration (FDA) investigation resulting in the agency issuing a warning

McNeil loses appeal on $10 million Children’s Motrin judgment

Posted: July 26, 2014

Johnson & Johnson subsidiary McNeil-PPC failed to convince the Pennsylvania Superior Court to overturn a $10 million verdict alleging the company’s Children’s Motrin caused a girl to develop a life threatening condition that burned her skin and caused her to

Pharmacy group wants black box warning added to antibiotic Levaquin

Posted: July 25, 2014

A University of South Carolina pharmacy group is petitioning the Food and Drug Administration (FDA) to put the strongest warning possible on Johnson & Johnson’s antibiotic Levaquin alerting consumers about the potential for cellular damage that could lead to serious diseases.